Alteika

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT ALTEYKA

Composition:

Active substance: 1 tablet contains dry extract of marshmallow root (Althaeae radix extractum siccum) (4:1) – 0.12 g;

Excipients: magnesium carbonate light, lactose monohydrate, aspartame (E 951), povidone, orange flavor, magnesium stearate.

Pharmaceutical form. Chewable tablets.

Main physicochemical properties. Greyish-brown tablets with specks, flat surface, a score line and bevelled edges.

Pharmacotherapeutic group.

Preparations used for cough and colds. Expectorants. Marshmallow roots.

ATC code R05C A05.

Pharmacological properties.

Pharmacodynamics.

A direct-acting expectorant. A herbal medicinal product containing dry extract of Althaea root, whose main biologically active substances are polysaccharides, as well as pectins, amino acids, and starch. The polysaccharides of the preparation are absorbed into the blood, partially excreted by bronchial glands, and exert a coating, softening, and anti-inflammatory effect on the mucous membrane of the upper respiratory tract. They slightly increase the secretion of the liquid component of bronchial mucus and normalize its rheological properties (viscosity, elasticity, adhesiveness). The medicinal product enhances bronchiolar peristaltic movements and the motor function of bronchial ciliated epithelium, promoting the expulsion of sputum.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications.

As part of complex treatment of acute and chronic inflammatory diseases of the respiratory organs: laryngitis, tracheitis, bronchitis, bronchial asthma, whooping cough.

Contraindications.

Hypersensitivity to the components of the drug; diabetes mellitus.

Interaction with other medicinal products and other types of interactions.

Concomitant use with antitussive agents (codeine) is not recommended.

Special precautions for use.

The drug should not be prescribed to patients with such rare hereditary disorders as fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency.

Due to the presence of aspartame in the medicinal product, it is contraindicated in patients with phenylketonuria.

Use during pregnancy or breastfeeding.

There is no experience with the use of the medicinal product during pregnancy or breastfeeding.

Ability to influence reaction rate when driving or operating machinery.

No effect.

Dosage and Administration.

Take orally. Administer before meals, chew, and swallow with a small amount of water.

For adults and children aged 14 years and older: 1 tablet 4–6 times daily.

Dosage for children by age:

7–14 years: 1 tablet 3–4 times daily;

3–7 years: ½ tablet 3–4 times daily.

Duration of treatment is determined individually by a physician, usually ranging from 7 days to 2 weeks.

Children.

For use in children aged 3 years and older.

Overdose.

Cases of overdose have not been reported.

Side effects.

In some cases, allergic reactions are possible, including urticaria and itching.

If any adverse reactions occur, discontinue treatment and consult a physician.

Shelf life.

3 years.

Storage conditions.

Store in a dry place at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

No. 20 (10×2), No. 50 (10×5) in blisters in a carton.

Availability category.

Over-the-counter.

Manufacturer/Marketing Authorization Holder.

TOV "Ternopharm".

Manufacturer's address and place of business activity / Holder's address.

TOV "Ternopharm".

46010, Ternopil, Fabrychna St., 4, Ukraine.

Tel./Fax: (0352) 521-444, www.ternopharm.com.ua